| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1517/14656566.8.9.1245 |
| P698 | PubMed publication ID | 17563260 |
| P2093 | author name string | Andrew M Roecker | |
| Scott D Pope | |||
| P2860 | cites work | An experimental study of vancomycin-induced cochlear damage. | Q50560147 |
| Antihistamine prophylaxis permits rapid vancomycin infusion. | Q51438981 | ||
| High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. | Q52081441 | ||
| Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. | Q52234767 | ||
| Standardization and quality assurance for antimicrobial resistance surveillance of Streptococcus pneumoniae and Staphylococcus aureus within the European Antimicrobial Resistance Surveillance System (EARSS). | Q54022285 | ||
| Bacteremia due to Staphylococcus aureus with reduced susceptibility to vancomycin. | Q54055447 | ||
| Susceptibility of 302 methicillin-resistant Staphylococcus aureus isolates from 20 European university hospitals to vancomycin and alternative antistaphylococcal compounds. SENTRY Participants Group. | Q54079431 | ||
| Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. | Q54095666 | ||
| The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. | Q54105049 | ||
| Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. | Q54125099 | ||
| Continuous infusion of vancomycin in methicillin-resistant staphylococcus infection. | Q54149026 | ||
| In-vitro comparison of the post-antibiotic effect of vancomycin and teicoplanin. | Q54318905 | ||
| Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections. | Q54320188 | ||
| World-wide antibiotic resistance in methicillin-resistant Staphylococcus aureus. | Q54357571 | ||
| Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. | Q55067143 | ||
| Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia | Q22241905 | ||
| Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981 | Q24671879 | ||
| Staphylococcus aureus infections | Q28131787 | ||
| Whole genome sequencing of meticillin-resistant Staphylococcus aureus | Q28202807 | ||
| Antibiotic resistance of bacteria in biofilms | Q28207706 | ||
| Nephrotoxicity of vancomycin, alone and with an aminoglycoside | Q28335291 | ||
| Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms | Q28374448 | ||
| Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know | Q31704853 | ||
| Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study | Q31918107 | ||
| Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surve | Q33181940 | ||
| Vancomycin-induced immune thrombocytopenia. | Q33374388 | ||
| Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model | Q33593883 | ||
| Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections | Q33836490 | ||
| Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group | Q33852247 | ||
| Outcome assessment of minimizing vancomycin monitoring and dosing adjustments | Q33860155 | ||
| Vancomycin resistance in staphylococci | Q33906522 | ||
| First report of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Thailand | Q33971217 | ||
| Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit | Q33979524 | ||
| Comparative In vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens | Q33981048 | ||
| Practice guidelines for the management of bacterial meningitis | Q33982444 | ||
| Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study | Q33982863 | ||
| Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin | Q34107062 | ||
| Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene | Q34188059 | ||
| Vancomycin susceptibility of oxacillin-resistant Staphylococcus aureus isolates causing nosocomial bloodstream infections | Q34198417 | ||
| Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study | Q34268116 | ||
| Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. American Heart Association | Q34288403 | ||
| New developments in diagnosis and treatment of infection in orthopedic implants | Q34326492 | ||
| Clonal spread of Staphylococcus aureus heterogeneously resistant to vancomycin in a university hospital in Korea. | Q34455373 | ||
| Emergence, mechanism, and clinical implications of reduced glycopeptide susceptibility in Staphylococcus aureus | Q34471268 | ||
| Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance? | Q44379429 | ||
| Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia | Q44453815 | ||
| Penetration of vancomycin into human lung tissue | Q44470518 | ||
| Outcome of Staphylococcus aureus bacteremia in patients with eradicable foci versus noneradicable foci | Q44573505 | ||
| Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia | Q44647040 | ||
| Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin | Q44721295 | ||
| Seeking vancomycin resistant Staphylococcus aureus among patients with vancomycin-resistant enterococci | Q44866281 | ||
| Frequency of reduced vancomycin susceptibility and heterogeneous subpopulation in persistent or recurrent methicillin-resistant Staphylococcus aureus bacteremia | Q44883937 | ||
| Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy | Q44959085 | ||
| Vancomycin-induced deletion of the methicillin resistance gene mecA in Staphylococcus aureus | Q44970445 | ||
| Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections | Q45127594 | ||
| Vancomycin-resistant Staphylococcus aureus in a bone marrow transplantation unit | Q45138934 | ||
| Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin | Q45199316 | ||
| Heterogeneous vancomycin-resistant Staphylococcus aureus (hetero-VISA) in Singapore | Q45233899 | ||
| Clinical isolates of Staphylococcus aureus from 1987 and 1989 demonstrating heterogeneous resistance to vancomycin and teicoplanin | Q45255740 | ||
| High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity | Q45302930 | ||
| Low colonization prevalence of Staphylococcus aureus with reduced vancomycin susceptibility among patients undergoing hemodialysis in the San Francisco Bay area. | Q45950832 | ||
| Antibacterial activity of linezolid and vancomycin in an in vitro pharmacodynamic model of gram-positive catheter-related bacteraemia | Q46425775 | ||
| Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus | Q46429720 | ||
| Antibiotic pharmacodynamics in cerebrospinal fluid | Q48343041 | ||
| Pathogenesis of catheter-related infections: lessons for new designs. | Q34669345 | ||
| Staphylococcus aureus bone and joint infection | Q34722412 | ||
| Vancomycin-resistant Staphylococcus aureus: a real and present danger? | Q34743797 | ||
| The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus. | Q34762753 | ||
| Efficacy and safety of linezolid in the treatment of skin and soft tissue infections | Q34781663 | ||
| Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q34783668 | ||
| Morphological and genetic differences in two isogenic Staphylococcus aureus strains with decreased susceptibilities to vancomycin | Q34823746 | ||
| Methicillin-resistant Staphylococcus aureus in ophthalmology, occurrence, sanitation measures and hygienic precautions | Q34865051 | ||
| Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis | Q34885043 | ||
| Evolution of a vancomycin-intermediate Staphylococcus aureus strain in vivo: multiple changes in the antibiotic resistance phenotypes of a single lineage of methicillin-resistant S. aureus under the impact of antibiotics administered for chemotherap | Q34975155 | ||
| Vancomycin penetration of uninfected pleural fluid exudate after continuous or intermittent infusion | Q35013838 | ||
| Staphylococcus aureus with Heterogeneous Resistance to Vancomycin: Epidemiology, Clinical Significance, and Critical Assessment of Diagnostic Methods | Q35541702 | ||
| Low-level vancomycin resistance in Staphylococcus aureus--an Australian perspective. | Q36025384 | ||
| Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia | Q37064359 | ||
| Derivatives of a vancomycin-resistant Staphylococcus aureus strain isolated at Hershey Medical Center. | Q37625160 | ||
| Clinical significance of Staphylococcus aureus in cystic fibrosis | Q37808887 | ||
| Vancomycin therapeutic drug monitoring: is it necessary? | Q38566835 | ||
| A new type of penicillin resistance of Staphylococcus aureus | Q39423863 | ||
| Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. | Q39474811 | ||
| Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices | Q39771366 | ||
| Antibiotic-tolerant Staphylococcus aureus | Q40398675 | ||
| Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus | Q40542104 | ||
| Comparison of Tn1546-like elements in vancomycin-resistant Staphylococcus aureus isolates from Michigan and Pennsylvania | Q40734214 | ||
| Non steady state and steady state PKS Bayesian forecasting and vancomycin pharmacokinetics in ICU adult patients | Q40802020 | ||
| Pharmacodynamics, pharmacokinetics, and therapeutic drug monitoring of glycopeptides | Q40839182 | ||
| Vancomycin monitoring: one or two serum levels? | Q40873553 | ||
| Vancomycin administration and monitoring reappraisal | Q40923535 | ||
| A prospective study of adverse reactions associated with vancomycin therapy | Q42226234 | ||
| Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination | Q42286407 | ||
| Mississippi mud in the 1990s: risks and outcomes of vancomycin-associated toxicity in general oncology practice | Q42537120 | ||
| Unstable vancomycin heteroresistance is common among clinical isolates of methiciliin-resistant Staphylococcus aureus | Q42868668 | ||
| Evidence for reduction in breakpoints used to determine vancomycin susceptibility in Staphylococcus aureus | Q42948108 | ||
| Poststernotomy mediastinitis due to Staphylococcus aureus: comparison of methicillin-resistant and methicillin-susceptible cases | Q43541559 | ||
| Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia | Q43781411 | ||
| Staphylococcus aureus meningitis in adults: a clinical comparison of infections caused by methicillin-resistant and methicillin-sensitive strains | Q43786212 | ||
| Once-daily versus twice-daily intravenous administration of vancomycin for infections in hospitalized patients | Q43829761 | ||
| Experimental study of the efficacy of vancomycin, rifampicin and dexamethasone in the therapy of pneumococcal meningitis | Q43895598 | ||
| Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections | Q43996924 | ||
| A multicenter evaluation of linezolid antimicrobial activity in North America | Q44019743 | ||
| Evidence for a continuum of decreased vancomycin susceptibility in unselected Staphylococcus aureus clinical isolates | Q44113970 | ||
| Four-year evaluation of frequency of occurrence and antimicrobial susceptibility patterns of bacteria from bloodstream infections in Latin American medical centers | Q44256800 | ||
| Skin and soft tissue infections in Latin American medical centers: four-year assessment of the pathogen frequency and antimicrobial susceptibility patterns | Q44256802 | ||
| Multicentre surveillance of antimicrobial resistance in enterococci and staphylococci from Colombian hospitals, 2001-2002. | Q44257270 | ||
| Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. | Q44302673 | ||
| Failure of vancomycin treatment in Staphylococcus aureus endocarditis. In vivo and in vitro observations | Q44369144 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multiple drug resistance | Q643839 |
| Staphylococcus aureus | Q188121 | ||
| vancomycin | Q424027 | ||
| P304 | page(s) | 1245-1261 | |
| P577 | publication date | 2007-06-01 | |
| P1433 | published in | Expert Opinion on Pharmacotherapy | Q5421212 |
| P1476 | title | Vancomycin for treatment of invasive, multi-drug resistant Staphylococcus aureus infections | |
| P478 | volume | 8 |
| Q43048123 | Hospital policies and practices on prevention and treatment of infections caused by methicillin-resistant Staphylococcus aureus |
| Q41776452 | Population Genomics of Reduced Vancomycin Susceptibility in Staphylococcus aureus. |
| Q38833957 | Proteome-wide antigen discovery of novel protective vaccine candidates against Staphylococcus aureus infection |
| Q37058032 | Role of folate antagonists in the treatment of methicillin-resistant Staphylococcus aureus infection |
| Q38054627 | Systematic review of efficacy, pharmacokinetics, and administration of intraventricular vancomycin in adults |
Search more.